ClinicalTrials.gov
public full text
Public Domain
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
This is a multicenter, prospective, observational study in which subjects will be treated with lenvatinib combined with TACE in un-resectable HCC patients who had not received systematic treatment or TACE treatment in the past.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma#1094043
- Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC#810115
- Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma#1102422
- TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma#804237
- A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma#879920
Record · ID 834745
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive